Status:
COMPLETED
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus. Data will be col...
Eligibility Criteria
Inclusion
- Adult patients, \>/= 18 years of age
- Chronic hepatitis C (detectable HCV RNA)
- Initiation of treatment with Pegasys and Copegus
Exclusion
- Participation in a clinical trial during the study
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
1155 Patients enrolled
Trial Details
Trial ID
NCT01200225
Start Date
February 1 2010
End Date
June 1 2013
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuilly-sur-Seine, France, 92521